Point72 Asset Management, L.P., Point72 Capital Advisors, Inc., and Steven A. Cohen filed a joint Schedule 13G with the SEC on November 9, 2026, disclosing beneficial ownership of 2,720,043 ordinary shares of Immunocore Holdings plc as of November 6, 2026.

Key Highlights

  • Aggregate beneficial ownership: Each reporting person disclosed beneficial ownership of 2,720,043 ordinary shares of Immunocore Holdings plc, representing 5.2% of the class.
  • Convertible notes component: The total includes 501,604 ordinary shares represented by ADSs issuable upon conversion of convertible notes held by Point72 Associates, LLC.
  • No sole voting or dispositive power: All 2,720,043 shares are reported exclusively under shared voting power and shared dispositive power; sole voting and sole dispositive power are each reported as 0.
  • Triggering event date: The date of the event requiring the filing is listed as November 6, 2026.
  • Joint filers: Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen filed jointly pursuant to a Joint Filing Agreement under Rule 13d-1(k).
  • Sub-advisor involvement: According to the filing, Cubist Systematic Strategies, LLC is a relying adviser on Point72 Asset Management's Form ADV and acts as a sub-advisor for a portion of the shares reported.

Point72 and Cohen Cross 5% Threshold in Immunocore via ADSs and Convertible Notes

The Schedule 13G, filed jointly on NASDAQ:IMCR, identifies three reporting persons: Point72 Asset Management, L.P. (a Delaware limited partnership), Point72 Capital Advisors, Inc. (a Delaware corporation, which the filing describes as the general partner of Point72 Asset Management), and Steven A. Cohen, a United States citizen. According to the filing, Mr. Cohen controls each of Point72 Asset Management and Point72 Capital Advisors, Inc. All three reporting persons report the same aggregate beneficial ownership figure of 2,720,043 ordinary shares, each with 0 sole voting power and 0 sole dispositive power.

The filing states that the ordinary shares are represented by American Depositary Shares (ADSs) quoted on the Nasdaq Global Market under the symbol "IMCR," with each ADS representing one ordinary share. The 2,720,043 figure includes 501,604 ordinary shares represented by ADSs issuable upon conversion of convertible notes held by Point72 Associates, LLC, an investment fund managed by Point72 Asset Management. The filing notes that Point72 Asset Management "maintains investment and voting power with respect to the securities held by Point72 Associates" pursuant to an investment management agreement.

The filing includes a standard disclaimer: "The filing of this statement should not be construed as an admission that any of the foregoing persons or any Reporting Person is, for the purposes of Section 13 of the Act, the beneficial owner of the Ordinary Shares reported herein." The filing also identifies Point72 Associates as having "the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, more than 5 percent of the outstanding" ordinary shares, as described in Item 6.

What Was Disclosed

Point72 Asset Management, Point72 Capital Advisors, Inc., and Steven A. Cohen jointly reported beneficial ownership of 2,720,043 Immunocore ordinary shares, equal to 5.2% of the class, as of November 6, 2026, including shares tied to convertible notes.